Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00314262
Status:
COMPLETED
Last Update Posted:
2014-10-24
First Post:
2006-04-11
Brief Title:
Phase III Study of Chemoprevention With EGFR and COX-2 Inhibitor
Sponsor:
Emory University
Organization:
Emory University
Study Overview
Official Title:
Phase III Study of Chemoprevention With Epidermal Growth Factor Receptor EGFR Tyrosine Kinase Inhibitor Erlotinib OSI-774 Tarceva and Cyclooxygenase-2 COX-2 Inhibitor Celecoxib in Premalignant Lesions of Head and Neck of Former Smokers
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate effect on cells and patient response to study medications assess side effects of these medications and evaluate chemicals in cells that may tell how the drug works before and after receiving the study medications
Detailed Description:
The purpose of this study is to evaluate the effect on cells and patient response to study medications assess the side effects of these medications and to evaluate chemicals in the cells that may tell how the drug works before and after receiving the study medications
Approximately 61 patients will participate at Emory Winship Cancer Institute and Emory Crawford W Long Hospital in Atlanta Georgia
Approximately 61 patients will participate at Emory Winship Cancer Institute and Emory Crawford W Long Hospital in Atlanta Georgia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None